Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements study found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://frankq466eqy5.thecomputerwiki.com/user